var data={"title":"Amyl nitrite: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Amyl nitrite: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5643?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=amyl-nitrite-drug-information\" class=\"drug drug_general\">see &quot;Amyl nitrite: Drug information&quot;</a> and <a href=\"topic.htm?path=amyl-nitrite-patient-drug-information\" class=\"drug drug_patient\">see &quot;Amyl nitrite: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051097\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidote, Cyanide</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Vasodilator, Coronary</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051089\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=amyl-nitrite-drug-information\" class=\"drug drug_general\">see &quot;Amyl nitrite: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cyanide toxicity:</b> Infants, Children, and Adolescents: Inhalation: 0.3 mL ampul crushed into a gauze pad and placed in front of the patient&rsquo;s mouth (or endotracheal tube if patient is intubated) to inhale over 15 to 30 seconds; repeat every minute until sodium nitrite can be administered. <b>Note:</b> Must separate administrations by at least 30 seconds to allow for adequate oxygenation; each ampul will last for ~3 minutes. Amyl nitrite is a temporary intervention that should only be used prehospital or if intravenous access cannot be obtained or until IV hydroxycobalamin or the sodium nitrite and sodium thiosulfate infusions are ready for administration (ATSDR 2001; Holstege 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cyanide toxicity:</b> Inhalation: 0.3 mL ampul crushed into a gauze pad and placed in front of the patient&rsquo;s mouth (or endotracheal tube if patient is intubated) to inhale over 15 to 30 seconds; repeat every minute until sodium nitrite can be administered (Mokhlesi 2003). <b>Note:</b> Must separate administrations by at least 30 seconds to allow for adequate oxygenation; each ampul will last for ~3 minutes. Amyl nitrite is a temporary intervention that should only be used prehospital or if intravenous access cannot be obtained or until IV hydroxocobalamin or the sodium nitrite and sodium thiosulfate infusions are ready for administration (ATSDR 2001; Holstege 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135335\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Liquid, for inhalation: USP: 85% to 103% (0.3 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135321\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051100\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer nasally via inhalation. The patient should be lying down during administration. Crush the ampul in a gauze pad and place in front of patient&rsquo;s mouth (or endotracheal tube if intubated) and allow patient to inhale for 15 to 30 seconds; repeat every minute until sodium nitrite can be administered. One ampul lasts for ~3 minutes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135347\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store in a cool place at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Protect from light. Contents are flammable; protect from open flame or spark.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051099\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of angina pectoris (FDA approved in adults); has also been used as an adjunct treatment of cyanide toxicity</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Note:</b> Although included as an FDA-approved use in the manufacturer&rsquo;s prescribing information, the use of amyl nitrite for patients experiencing angina pectoris has fallen out of favor. Newer nitrate compounds are more easily administered.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135369\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Cerebral ischemia, facial flushing, hypotension, orthostatic hypotension, shock, syncope, tachycardia, vasodilatation </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Dizziness, headache, increased intracranial pressure, restlessness </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Dermatitis, diaphoresis, pallor, skin irritation </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Fecal incontinence, nausea, vomiting </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Urinary incontinence </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Hemolytic anemia, methemoglobinemia  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Eye irritation, increased intraocular pressure  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135340\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glaucoma; recent head trauma or cerebral hemorrhage; pregnancy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">For cyanide poisoning: Concurrent carbon monoxide poisoning</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135324\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension: Amyl nitrite may cause severe hypotension; serious adverse effects may occur at doses less than the recommended therapeutic dose. Monitor for adequate perfusion and oxygenation; ensure patient is euvolemic. Use with caution in patients where the diagnosis of cyanide poisoning is uncertain, patients with preexisting diminished oxygen or cardiovascular reserve (eg, smoke inhalation victims, anemia, substantial blood loss, and cardiac or respiratory compromise) and in patients who may be susceptible to injury from vasodilation; the use of hydroxocobalamin is recommended in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Methemoglobinemia: Amyl nitrite may cause methemoglobin formation resulting in diminished oxygen-carrying capacity; serious adverse effects may occur at doses less than the recommended therapeutic dose. Monitor for adequate perfusion and oxygenation. Use with caution in patients where the diagnosis of cyanide poisoning is uncertain, patients with preexisting diminished oxygen or cardiovascular reserve (eg, smoke inhalation victims, anemia, substantial blood loss, and cardiac or respiratory compromise), and in patients at greater risk for developing methemoglobinemia (eg, congenital methemoglobin reductase deficiency); the use of hydroxocobalamin is recommended in these patients. Use with caution with concomitant medications known to cause methemoglobinemia (eg, nitroglycerin, phenazopyridine).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Aortic stenosis: Use with extreme caution or avoid in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia; considered by some to be a contraindication (Reagan, 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with coronary artery disease and patients with hypotension. Transient episodes of dizziness, weakness, syncope, and cerebral ischemia secondary to postural hypotension may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Increased intracranial pressure: Use with caution in patients with increased intracranial pressure; use is contraindicated in patient with recent head trauma or cerebral hemorrhage.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fire victims: Fire victims may present with both cyanide and carbon monoxide poisoning. In these patients, the induction of methemoglobinemia (due to amyl nitrite) is contraindicated until carbon monoxide levels return to normal due to the risk of tissue hypoxia. Methemoglobinemia decreases the oxygen-carrying capacity of hemoglobin and the presence of carbon monoxide prevents hemoglobin from releasing oxygen to the tissues. In this scenario, sodium thiosulfate may be used alone to promote the clearance of cyanide. Hydroxocobalamin, however, should be considered to avoid the nitrite-related problems and because sodium thiosulfate has a slow onset of action.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Methemoglobin reductase, which is responsible for converting methemoglobin back to hemoglobin, has reduced activity in pediatric patients. In addition, infants and young children have some proportion of fetal hemoglobin which forms methemoglobin more readily than adult hemoglobin. Therefore, pediatric patients (eg, neonates and infants &lt;6 months) are more susceptible to excessive nitrite-induced methemoglobinemia. Hydroxocobalamin will circumvent this problem and may be a more effective and rapid alternative.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnancy: Nitrites should be avoided due to fetal hemoglobin's susceptibility to oxidative stress.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Cyanide poisoning: Due to the risk for serious adverse effects, use with caution in patients where the diagnosis of cyanide poisoning is uncertain. However, if clinical suspicion of cyanide poisoning is high, treatment should not be delayed. Treatment of cyanide poisoning should include external decontamination and supportive therapy. Consider consultation with a poison control center at 1-800-222-1222.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Initiation of treatment: Collection of pretreatment blood cyanide concentrations does not preclude administration and should not delay administration in the emergency management of highly suspected or confirmed cyanide toxicity. Pretreatment levels may be useful as postinfusion levels may be inaccurate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Return of symptoms: Patients receiving treatment for acute cyanide toxicity must be monitored for return of symptoms for 24-48 hours; repeat therapy should be administered if symptoms return.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Smoke inhalation: Use nitrites cautiously in patients with cyanide poisoning related to smoke inhalation because methemoglobinemia and carboxyhemoglobinemia may worsen oxygen-carrying capacity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298751\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135329\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12728&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when nitric oxide is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the vasodilatory effect of Amyl Nitrite.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Riociguat: Amyl Nitrite may enhance the hypotensive effect of Riociguat. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracaine (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135331\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13315273\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Because amyl nitrite significantly decreases systemic blood pressure and therefore blood flow to the fetus, use is contraindicated in pregnancy (per manufacturer). In addition, fetal hemoglobin may be more susceptible methemoglobin conversion (Valenzuela, 1986). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051096\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor blood pressure and heart rate during therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyanide toxicity: Monitor for at least 24 to 48 hours after administration; hemoglobin/hematocrit; co-oximetry; serum lactate levels; venous-arterial PO<sub>2</sub> gradient; serum methemoglobin and oxyhemoglobin. Pretreatment cyanide levels may be useful diagnostically.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15589398\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Symptoms associated with blood cyanide levels:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flushing and tachycardia: 0.5 to 1 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obtundation: 1 to 2.5 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coma and respiratory depression: &gt;2.5 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Death: &gt;3 mcg/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2508782\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Relaxes vascular smooth muscle; decreases venous ratios and arterial blood pressure; reduces left ventricular work; decreases myocardial O<sub>2</sub> consumption. When used for cyanide poisoning, amyl nitrite promotes the formation of methemoglobin which competes with cytochrome oxidase for the cyanide ion. Cyanide combines with methemoglobin to form cyanomethemoglobin, thereby freeing the cytochrome oxidase and allowing aerobic metabolism to continue.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135339\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Angina: Within 30 seconds </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Angina: 3-15 minutes; Pharmacologic provocation of latent left ventricular outflow tract (LVOT) gradient in hypertrophic cardiomyopathy (HCM): ~30 seconds (Reagan, 2005) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Inhalation: Readily absorbed through respiratory tract </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: In the liver to form inorganic nitrates (less potent) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Amyl nitrite: &lt;1 hour; Methemoglobin: 1 hour </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion:Urine (~33%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322991\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Amyl Nitrite Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.3 mL (1): $0.63</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>The pricing data provided represent a median AWP and/or AAWP price for the brand and/or generic product, respectively. The pricing data should be used for benchmarking purposes only, and as such should not be used to set or adjudicate any prices for charging or reimbursement functions. Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038529\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Amyl Nitrite (NZ)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Agency for Toxic Substances and Disease Registry (ATSDR), &quot;Medical Management Guidelines for Hydrogen Cyanide (HCN),&quot; 2001. Available at <a href=\"http://www.atsdr.cdc.gov/MHMI/mmg8.pdf\" target=\"_blank\">http://www.atsdr.cdc.gov/MHMI/mmg8.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berlin CM Jr, &quot;The Treatment of Cyanide Poisoning in Children,&quot; <i>Pediatrics</i>, 1970, 46(5):793-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amyl-nitrite-pediatric-drug-information/abstract-text/4320419/pubmed\" target=\"_blank\" id=\"4320419\">4320419</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Geller RJ, Barthold C, Saiers JA, et al, &quot;Pediatric Cyanide Poisoning: Causes, Manifestations, Management, and Unmet Needs,&quot; <i>Pediatrics</i>, 2006, 118(5):2146-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amyl-nitrite-pediatric-drug-information/abstract-text/17079589/pubmed\" target=\"_blank\" id=\"17079589\">17079589</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gracia R and Shepherd G, &quot;Cyanide Poisoning and Its Treatment,&quot; <i>Pharmacotherapy</i>, 2004, 24(10):1358-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amyl-nitrite-pediatric-drug-information/abstract-text/15628833/pubmed\" target=\"_blank\" id=\"15628833\">15628833</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hall AH, Dart R, and Bogdan G, &ldquo;Sodium Thiosulfate or Hydroxocobalamin for the Empiric Treatment of Cyanide Poisoning?&rdquo; <i>Ann Emerg Med</i>, 2007, 49(6):806-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amyl-nitrite-pediatric-drug-information/abstract-text/19650716/pubmed\" target=\"_blank\" id=\"19650716\">19650716</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Holstege CP, Kirk MA. &ldquo;Cyanide and Hydrogen Sulfide,&rdquo; <i>Goldfrank's Toxicologic Emergencies.</i> 10th ed. Hoffman RS, Howland MA, Lewin NA, Nelson LS, et al, eds. New York, NY: McGraw-Hill Companies, Inc; 2015,<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amyl-nitrite-pediatric-drug-information/abstract-text/19650716/pubmed\" target=\"_blank\" id=\"19650716\">19650716</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Howland MA, &ldquo;Antidotes in Depth: Sodium and Amyl Nitrite,&rdquo; <i>Goldfrank's Toxicologic Emergencies</i>, 9th ed, Nelson LS, Hoffman RS, Lewin NA, et al, eds, New York, NY: McGraw-Hill Companies, Inc, 2011, 1519-22.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lavon O and Bentur Y, &quot;Does Amyl Nitrite Have a Role in the Management of Pre-Hospital Mass Casualty Cyanide Poisoning?&quot; <i>Clin Toxicol (Phila)</i>, 2010, 48(6):477-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amyl-nitrite-pediatric-drug-information/abstract-text/20653465/pubmed\" target=\"_blank\" id=\"20653465\">20653465</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo; <i>Chest</i>, 2003, 123(3):897-922.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amyl-nitrite-pediatric-drug-information/abstract-text/12628894/pubmed\" target=\"_blank\" id=\"12628894\">12628894</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nichol LM, Mills NL, and Starkey IR, &quot;Amyl Nitrite Induced Cerebral and Coronary Vasospasm,&quot; <i>QJM</i>, 2011, 104(1):83-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amyl-nitrite-pediatric-drug-information/abstract-text/20843773/pubmed\" target=\"_blank\" id=\"20843773\">20843773</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reagan BW, Helmcke F, and Kerut EK, &quot;Commonly Used Respiratory and Pharmacologic Interventions in the Echocardiography Laboratory,&quot; <i>Echocardiography</i>, 2005, 22(5):455-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amyl-nitrite-pediatric-drug-information/abstract-text/15901303/pubmed\" target=\"_blank\" id=\"15901303\">15901303</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Valenzuela A, Guerra R, Lazcano L, et al, &ldquo;Differential Prooxidative Effect of Adult and Fetal Hemoglobin,&quot; <i>FEBS Lett</i>, 1986, 196(2):353-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amyl-nitrite-pediatric-drug-information/abstract-text/2419158/pubmed\" target=\"_blank\" id=\"2419158\">2419158</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12728 Version 85.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1051097\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1051089\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F135335\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F135321\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1051100\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F135347\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1051099\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F135369\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F135340\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F135324\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298751\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F135329\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F135331\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13315273\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1051096\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F15589398\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F2508782\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F135339\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322991\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038529\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12728|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=amyl-nitrite-drug-information\" class=\"drug drug_general\">Amyl nitrite: Drug information</a></li><li><a href=\"topic.htm?path=amyl-nitrite-patient-drug-information\" class=\"drug drug_patient\">Amyl nitrite: Patient drug information</a></li></ul></div></div>","javascript":null}